Danazol a new perspective in the treatment of htlv-l associated myelopathy (preliminary report)

Melo, Ailton; Moura, Luciana; Meireles, Ana; Costa, Gerçonita

doi:10.1590/S0004-282X1992000300025

Abstracts

We investigated the efficacy of danazol treatment in eight patients with HTLV-l associated myelopathy/tropical spastic paraparesis (HAM/TSP). Treatment with danazol yielded clinical improvement of urinary control and gait disturbances in 7 out of the 8 patients. The improvement was noted within 15 days of danazol administration. Analysis of factors of relevance to the clinical improvement with danazol showed that the beneficial response was preferentially found in females.

tropical spastic paraparesis; HTLV-1; myelopathy; danazol; treatment of HAM

Investigamos a eficácia do danazol, um andrógeno sintético, no tratamento de 5 mulheres e 3 homens com mielopatia associada a HTDV-1. Dentro do período de 15 dias após o início da administração da droga houve melhora significativa do controle urinário e aumento da força muscular em membros inferiores. Os resultados clínicos obtidos foram mais pronunciados em mulheres que em homens.

paraparesia espástica tropical; HTLV-1; mielopatia; danazol; tratamento da HAM

Danazol a new perspective in the treatment of htlv-l associated myelopathy (preliminary report)

Danazol: uma nova perspectiva no tratamento da mielopatia associada a HTLV-1 (relato preliminar)

Ailton Melo; Luciana Moura; Ana Meireles; Gerçonita Costa

Federal University of Bahia (UFBA), Salvador

SUMMARY

We investigated the efficacy of danazol treatment in eight patients with HTLV-l associated myelopathy/tropical spastic paraparesis (HAM/TSP). Treatment with danazol yielded clinical improvement of urinary control and gait disturbances in 7 out of the 8 patients. The improvement was noted within 15 days of danazol administration. Analysis of factors of relevance to the clinical improvement with danazol showed that the beneficial response was preferentially found in females.

Key words: tropical spastic paraparesis, HTLV-1, myelopathy, danazol, treatment of HAM.

RESUMO

Investigamos a eficácia do danazol, um andrógeno sintético, no tratamento de 5 mulheres e 3 homens com mielopatia associada a HTDV-1. Dentro do período de 15 dias após o início da administração da droga houve melhora significativa do controle urinário e aumento da força muscular em membros inferiores. Os resultados clínicos obtidos foram mais pronunciados em mulheres que em homens.

Palavras-chave: paraparesia espástica tropical, HTLV-1, mielopatia, danazol, tratamento da HAM.

Texto completo disponível apenas em PDF.

Full text available only in PDF format.

Dr. Ailton Melo Departamento de Ciências da Biorregulação, Instituto de Ciências da Saúde, UFBA - Av. Reitor Miguel Calmon s/n - 40210 Salvador BA - Brasil.

1. Donaldson VH. Danazol. Am J Med 1989, 87:49-55.
2. Gout O, Gessain A, Iba-Zizen M, Kouzan S, Zolgert F, de The G, Lyon-Caen O. The effect of zidovudine on chronic myelopathy associated with HTLV-1. J Neurol 1991, 238:108-109.
3. Graff RJ, Lappe M, Snell GD. The influence of the gonads and adrenal glands on the immune response to skin grafts. Transplantation 1969, 7:105.
4. Harrington WJ Jr, Sheremata WA, Snodgrass SR, Emerson S, Phillips S, Berger JR. Tropical spastic paraparesis/HTL.V-1 associated myelopathy (TSF/HAM) : treatment with an anabolic steroid danazol. AIDS Res Hum Retrov 1991, 7:1031-1034.
5. Izumo S. Usuko K, Osame M, Arimura K, Igata A. Effect of alpha-interferon treatment on HTL.V-1 associated myelopathy (HAM). Neuroloy 1988, 38 (Suppl 1):242.
6. Kuroda Y, Takiashima H, Ikeda A, Endo C, Neshige R, Kakigi R, Shibasaki H. Treatment of HTLV-l-associated myelopathy with high-dose intravenous gammaglobulin. J Neurol 1991, 238:309-314.
7. Meireles A, Moreira ED Jr, Moreno-Carvalho OA, Badaro R, Melo A. HTLV-1 associated myelopathy in Salvador (northeastern Brazil). Arq Neuro-Psiquiat (São Paulo) 1992, 50:189-190.
8. Moreno-Carvalho OA, Santos JI, Di Gredico G, Galvão-Castro B. Evidence of preferential female prevalence of HTL.V-1 associated tropical spastic paraparesis in Bahia-Brazil. Arq Neuro-Psiquiat (São Paulo) 1992, 50:183-188.
9. Osame M, Igata A, Matsumoto M, Usuku K, Kitajima I, Takahashi K. On the discovery of a new clinical entity: human T-cell lymphotropic virus type I associated myelopathy (HAM). Adv Neurol Sci (Tokyo) 1987, 31:727-745.
10. Spina-França A, Livramento JA, Machado LR, Gomes HR, Vianna LS, Oastro LHM, No-brega JPS, Bacheschi LA. HTLV-1 antibodies in serum and cerebrospinal fluid in tropical spastic paraparesis in Brazil. Arq Neuro-Psiquiat 1990, 48:441-447.
11. Roman GC. The neuroepidemiology of tropical spastic paraparesis. Ann Neurol 1988. 23 (Suppl):113-130.

Publication Dates

Publication in this collection
22 Feb 2011
Date of issue
Sept 1992

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

[1] 1. Donaldson VH. Danazol. Am J Med 1989, 87:49-55.

[2] 2. Gout O, Gessain A, Iba-Zizen M, Kouzan S, Zolgert F, de The G, Lyon-Caen O. The effect of zidovudine on chronic myelopathy associated with HTLV-1. J Neurol 1991, 238:108-109.

[3] 3. Graff RJ, Lappe M, Snell GD. The influence of the gonads and adrenal glands on the immune response to skin grafts. Transplantation 1969, 7:105.

[4] 4. Harrington WJ Jr, Sheremata WA, Snodgrass SR, Emerson S, Phillips S, Berger JR. Tropical spastic paraparesis/HTL.V-1 associated myelopathy (TSF/HAM) : treatment with an anabolic steroid danazol. AIDS Res Hum Retrov 1991, 7:1031-1034.

[5] 5. Izumo S. Usuko K, Osame M, Arimura K, Igata A. Effect of alpha-interferon treatment on HTL.V-1 associated myelopathy (HAM). Neuroloy 1988, 38 (Suppl 1):242.

[6] 6. Kuroda Y, Takiashima H, Ikeda A, Endo C, Neshige R, Kakigi R, Shibasaki H. Treatment of HTLV-l-associated myelopathy with high-dose intravenous gammaglobulin. J Neurol 1991, 238:309-314.

[7] 7. Meireles A, Moreira ED Jr, Moreno-Carvalho OA, Badaro R, Melo A. HTLV-1 associated myelopathy in Salvador (northeastern Brazil). Arq Neuro-Psiquiat (São Paulo) 1992, 50:189-190.

[8] 8. Moreno-Carvalho OA, Santos JI, Di Gredico G, Galvão-Castro B. Evidence of preferential female prevalence of HTL.V-1 associated tropical spastic paraparesis in Bahia-Brazil. Arq Neuro-Psiquiat (São Paulo) 1992, 50:183-188.

[9] 9. Osame M, Igata A, Matsumoto M, Usuku K, Kitajima I, Takahashi K. On the discovery of a new clinical entity: human T-cell lymphotropic virus type I associated myelopathy (HAM). Adv Neurol Sci (Tokyo) 1987, 31:727-745.

[10] 10. Spina-França A, Livramento JA, Machado LR, Gomes HR, Vianna LS, Oastro LHM, No-brega JPS, Bacheschi LA. HTLV-1 antibodies in serum and cerebrospinal fluid in tropical spastic paraparesis in Brazil. Arq Neuro-Psiquiat 1990, 48:441-447.

[11] 11. Roman GC. The neuroepidemiology of tropical spastic paraparesis. Ann Neurol 1988. 23 (Suppl):113-130.